The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and that are formulated for delivery to the pulmonary system via inhalation.

Methods of prophylactically treating fibrotic conditions using a synthetic lamellar body composition are provided, such as conditions of the lung, skin, gastrointestinal system, genitourinary system, heart, peritoneum, kidney, liver, and mucosa. In particular the present invention is concerned with lung injury which may be characterised by increased pulmonary vascular permeability. Suitably the lamellar body composition for use in the prophylactic treatment of fibrotic or pro-fibrotic conditions comprises phosphatidylcholine, cholesterol and optionally at least one phospholipid selected from phosphatidyl serine, phosphatidyl glycerol and phosphatidyl inositol to provide an anionic lamellar body.

Provided are compositions comprising silk fibroin, perfluorocarbon (PFC), and surfactant, and methods of use thereof. The compositions can further comprise a drug, an antibody, or a vaccine. Compositions of the invention are useful in the treatment of certain lung diseases and conditions, including in particular those characterized by surfactant deficiency. Compositions of the invention are particularly useful in the treatment of respiratory distress syndrome (RDS). Also provided are methods for making the compositions, and kits comprising components of the compositions.

The present invention relates to a pulmonary surfactant-based anticancer drug. The anticancer drug encapsulated in a liposome made of a pulmonary surfactant can effectively target lung cancer cells, especially adenocarcinomas derived from type II alveolar cells, and has low toxicity and excellent structural stability.

The present disclosure relates to a synthetic Tngara frog foam composition. The synthetic Tngara frog foam composition comprises six synthetically synthesized ranaspumin proteins (RSN-1 to RSN-6) wherein only the active segments of the RSN proteins are synthesized and six synthetically synthesized polysaccharides comprising four tetrasaccharides, a heptasaccharide and a nonasaccharide. Multiple novel applications of the foam are described.

The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

The present disclosure relates to a synthetic Tngara frog foam composition. The synthetic Tngara frog foam composition comprises six synthetically synthesized ranaspumin proteins (RSN-1 to RSN-6) wherein only the active segments of the RSN proteins are synthesized and six synthetically synthesized polysaccharides comprising four tetrasaccharides, a heptasaccharide and a nonasaccharide. Multiple novel applications of the foam are described.

In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption. Dilute surfactant or SP-C solution could be administered via either the trachea or the vasculature. Either solution could be delivered in the absence or presence of albumin or alternative facilitating solute, to lower surface tension and lessen ventilation injury of the heterogeneously flooded lung.

Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.

Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders.